All In Biotech

Drug Trial Radar · NCT04008706

Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia.

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

552

Actual

Start

Sep 17, 2019

Primary completion

Nov 4, 2025

Study completion Nov 4, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Jul 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: treatment-naive (TN), relapsed/refractory (R/R), and prior ibrutinib therapy. For this study, participants in the UK will be enrolled ONLY into the R/R cohort or the prior ibrutinib cohort. Participants in the US will be enrolled ONLY into the TN or R/R cohort. Participants will remain on study intervention until completion of 48 cycles (28 days per cycle), or until study intervention discontinuation due to, for example disease progression, or toxicity, withdrawal of consent, loss to follow-up, death, or study termination by the sponsor whichever occurs first. The duration of the study will be approximately 72 months from the first participant enrolled. This duration includes an estimated 24-month recruitment time and an assumed 48 cycles of study intervention (28 days per cycle); additional study time will be accrued during the Disease Follow up period for those participants remaining on study intervention after completion of 48 cycles prior to the final data cutoff (DCO) (the amount of time will vary by participant).

Conditions

  • Chronic Lymphocytic Leukemia

Interventions

  • AcalabrutinibDrug

    Acalabrutinib will be administered as one 100 mg capsule taken orally, twice daily with 8 ounces (approximately 240 mL) of water.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Up to safety follow-up period (about 30 days from last dose) (approximately 74 months)

Locations

108 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Chandler, Arizona

  • Research Site

    Long Beach, California

  • Research Site

    Redlands, California

  • Research Site

    Whittier, California

  • Research Site

    Fort Myers, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Marietta, Georgia

  • Research Site

    Normal, Illinois

  • Research Site

    Peoria, Illinois

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Saint Cloud, Minnesota

  • Research Site

    Kansas City, Missouri

  • Research Site

    Bethlehem, Pennsylvania

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Dallas, Texas

  • Research Site

    Adelaide, Australia

  • Research Site

    Bedford Park, Australia

  • Research Site

    Clayton, Australia

  • Research Site

    Fitzroy, Australia

  • Research Site

    Nedlands, Australia

  • Research Site

    South Brisbane, Australia

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Curitiba, Brazil

  • Research Site

    Goiânia, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Ribeirão Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Victoria, British Columbia, Canada

  • Research Site

    Winnipeg, Manitoba, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    Brampton, Ontario, Canada

  • Research Site

    Newmarket, Ontario, Canada

Showing 40 of 108 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.